Myocarditis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
m Bot: Removing from Primary care |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Effective measures for the [[secondary prevention]] of myocarditis include, [[clinical]] evaluation, [[ECG]], and [[echocardiography]]. [[CMR]], [[cardiac]] [[CT scan]], [[Nuclear|nuclear assessment]] in [[patients]] that [[echocardiography]] is undiagnostic. [[Patients]] should udergo [[Cardiac function curve|cardiac function]] assessment at one and six months and yearly after that. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
* Effective measures for the [[secondary prevention]] of myocarditis include:<ref name="CaforioPankuweit2013">{{cite journal|last1=Caforio|first1=A. L. P.|last2=Pankuweit|first2=S.|last3=Arbustini|first3=E.|last4=Basso|first4=C.|last5=Gimeno-Blanes|first5=J.|last6=Felix|first6=S. B.|last7=Fu|first7=M.|last8=Helio|first8=T.|last9=Heymans|first9=S.|last10=Jahns|first10=R.|last11=Klingel|first11=K.|last12=Linhart|first12=A.|last13=Maisch|first13=B.|last14=McKenna|first14=W.|last15=Mogensen|first15=J.|last16=Pinto|first16=Y. M.|last17=Ristic|first17=A.|last18=Schultheiss|first18=H.-P.|last19=Seggewiss|first19=H.|last20=Tavazzi|first20=L.|last21=Thiene|first21=G.|last22=Yilmaz|first22=A.|last23=Charron|first23=P.|last24=Elliott|first24=P. M.|title=Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases|journal=European Heart Journal|volume=34|issue=33|year=2013|pages=2636–2648|issn=0195-668X|doi=10.1093/eurheartj/eht210}}</ref><ref>{{Cite journal | |||
| author = [[C. L. Miklozek]], [[E. M. Kingsley]], [[C. S. Crumpaker]], [[J. F. Modlin]], [[H. D. Royal]], [[P. C. Come]], [[R. Mark]] & [[W. H. Abelmann]] | |||
| title = Serial cardiac function tests in myocarditis | |||
| journal = [[Postgraduate medical journal]] | |||
| volume = 62 | |||
| issue = 728 | |||
| pages = 577–579 | |||
| year = 1986 | |||
| month = June | |||
| doi = 10.1136/pgmj.62.728.577 | |||
| pmid = 3774697 | |||
}}</ref> | |||
**[[Clinical]] evaluation | |||
**[[ECG]] | |||
**[[Echocardiography]] | |||
**[[CMR]], [[cardiac]] [[CT scan]], [[Nuclear|nuclear assessment]] in [[patients]] that [[echocardiography]] is undiagnostic | |||
* [[Patients]] should undergo [[Cardiac function curve|cardiac function]] assessment at one and six months and yearly after that. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Up-To-Date | [[Category:Up-To-Date]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Intensive care medicine]] | [[Category:Intensive care medicine]] | ||
Latest revision as of 22:51, 29 July 2020
|
Myocarditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myocarditis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Myocarditis secondary prevention |
|
Risk calculators and risk factors for Myocarditis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
Effective measures for the secondary prevention of myocarditis include, clinical evaluation, ECG, and echocardiography. CMR, cardiac CT scan, nuclear assessment in patients that echocardiography is undiagnostic. Patients should udergo cardiac function assessment at one and six months and yearly after that.
Secondary Prevention
- Effective measures for the secondary prevention of myocarditis include:[1][2]
- Clinical evaluation
- ECG
- Echocardiography
- CMR, cardiac CT scan, nuclear assessment in patients that echocardiography is undiagnostic
- Patients should undergo cardiac function assessment at one and six months and yearly after that.
References
- ↑ Caforio, A. L. P.; Pankuweit, S.; Arbustini, E.; Basso, C.; Gimeno-Blanes, J.; Felix, S. B.; Fu, M.; Helio, T.; Heymans, S.; Jahns, R.; Klingel, K.; Linhart, A.; Maisch, B.; McKenna, W.; Mogensen, J.; Pinto, Y. M.; Ristic, A.; Schultheiss, H.-P.; Seggewiss, H.; Tavazzi, L.; Thiene, G.; Yilmaz, A.; Charron, P.; Elliott, P. M. (2013). "Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases". European Heart Journal. 34 (33): 2636–2648. doi:10.1093/eurheartj/eht210. ISSN 0195-668X.
- ↑ C. L. Miklozek, E. M. Kingsley, C. S. Crumpaker, J. F. Modlin, H. D. Royal, P. C. Come, R. Mark & W. H. Abelmann (1986). "Serial cardiac function tests in myocarditis". Postgraduate medical journal. 62 (728): 577–579. doi:10.1136/pgmj.62.728.577. PMID 3774697. Unknown parameter
|month=ignored (help)